Related Experiment Video
Updated: May 31, 2026

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
Published on: September 16, 2018
Imiquimod as an adjuvant treatment measure for desmoplastic trichoepithelioma
Sang-Hee Seo1, Gun-Wook Kim, Hyun-Woo Sung
1Department of Dermatology and Medical Research Institute, Yangsan Pusan National University Hospital, Yangsan, Korea.
Abstract:
Desmoplastic trichoepithelioma is a rare benign adnexal tumor. Although it is a benign lesion, patients often want to treat it due to cosmetic concerns when it occurs in an easily visible site. For our two cases, topical 5% imiquimod was an attractive treatment option as it is applied by the patients themselves and it has minimal side effects, including leaving no scar. However, the lesions recurred after clinical remission. To the best of our knowledge, this is the only report on utilizing imiquimod to treat a benign adnexal tumor, and especially desmoplastic trichoepithelioma.
Related Concept Videos
Tumor Immunotherapy
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...